A drug born from the treatment of obesity has revealed a deeper gift: the capacity to shield the human heart. Researchers presenting at the European Congress of Obesity in May 2024 found that semaglutide — the compound behind Wegovy and Ozempic — reduced the risk of heart attack, stroke, and cardiovascular death by 20 percent across a trial of more than 17,000 adults in 41 countries. What unsettles easy explanation is that this protection held even when weight loss was modest, suggesting the drug acts on the cardiovascular system through pathways medicine has yet to fully name. In the traditio
Semaglutide cuts heart attack risk by 20%, potentially rivaling statins as medical breakthrough
Something else is going on that benefits the cardiovascular system
Mark
So the headline is that semaglutide cuts heart attack risk by 20 percent. But I'm reading that the weight loss itself was only about 10 percent. How does a 10 percent weight loss produce a 20 percent reduction in cardiovascular events?
Mimi
That's the crucial finding. The researchers controlled for weight loss and found the benefit held even for people who lost very little weight. It suggests the drug is doing something to the cardiovascular system directly—protecting blood vessels, reducing inflammation, stabilizing plaques. We don't fully understand the mechanism yet.
Luke
But we should be careful here. The study shows correlation, not causation. We know semaglutide users had fewer events. We don't know exactly why. The researchers are saying it's not just weight loss, but they're also saying "something else is going on." That's honest, but it's also saying we don't have the full picture.
Mark
The study involved 17,604 people over 40 months. That's a substantial trial. Are there any limitations we should know about?
Mimi
The participants all had a history of cardiovascular events already—they weren't healthy people. So this is about secondary prevention, not primary prevention. It's about people who've already had a heart attack or stroke.
Luke
Right. And they were all overweight or obese to begin with. We don't know if semaglutide would have the same protective effect in lean people, or in people without prior cardiovascular disease. The study is strong within its population, but we shouldn't extrapolate too far.
Mark
Deanfield compared this to statins in the 1990s. Is that comparison fair?
Mimi
Statins lowered cholesterol and reduced heart disease risk through a well-understood mechanism. We knew why they worked. With semaglutide, we're seeing the benefit but not the full mechanism. So it's similar in scale—potentially transformative—but different in our understanding of it.
Luke
And statins took decades to become standard of care. The comparison is useful for thinking about impact, but it shouldn't make us think this is settled science. We're at the beginning of understanding semaglutide's cardiovascular effects, not the end.
Mark
What about the newer drug, retatrutide? Is that going to replace semaglutide?
Mimi
It's too early to say. Retatrutide showed 24 percent weight loss in a 48-week trial—much more than semaglutide. But it's still in phase 2 testing. We don't have long-term safety data, and we don't have cardiovascular outcome data yet.
Luke
And the retatrutide trial was much smaller—338 people versus 17,604 for semaglutide. We're comparing a small, short-term weight loss study to a large, long-term cardiovascular outcomes study. They're measuring different things. Retatrutide might be more effective for weight loss, but we don't know yet if it's better for heart health.
Der Puls
- A 20% reduction in major cardiovascular events — heart attacks, strokes, and cardiac deaths — has cardiologists reaching for comparisons to the statin revolution of the 1990s.
- The finding that heart protection persists even with minimal weight loss has disrupted the assumption that semaglutide's value is primarily about the number on a scale.
- With 7.6 million people in the UK living with heart or circulatory disease, the pressure on the NHS to expand prescribing beyond weight loss is intensifying rapidly.
- Treasury officials and health economists are already calculating the downstream gains — fewer sick days, greater workforce productivity — as the drug's cost trajectory trends downward.
- A rival compound, retatrutide, is advancing through trials with weight-loss results of 24 percent over 48 weeks, signaling that the ceiling of this pharmacological era may not yet be in sight.
A drug born from the treatment of obesity has revealed a deeper gift: the capacity to shield the human heart. Researchers presenting at the European Congress of Obesity in May 2024 found that semaglutide — the compound behind Wegovy and Ozempic — reduced the risk of heart attack, stroke, and cardiovascular death by 20 percent across a trial of more than 17,000 adults in 41 countries. What unsettles easy explanation is that this protection held even when weight loss was modest, suggesting the drug acts on the cardiovascular system through pathways medicine has yet to fully name. In the tradition of statins before it, semaglutide may be quietly reordering what we believe possible in the long fight against chronic disease.
A weight-loss injection used by millions may be on the verge of redefining how medicine treats heart disease. Researchers from University College London, presenting at the European Congress of Obesity in May 2024, revealed that semaglutide — the active ingredient in Wegovy and Ozempic — cut the risk of heart attack, stroke, and cardiovascular death by 20 percent in a large international trial. Leading cardiologists have begun comparing its potential to statins, the cholesterol-lowering drugs that transformed cardiac care in the 1990s.
The trial followed 17,604 adults aged 45 and older across 41 countries, all with a BMI above 27 and a history of cardiovascular events. Over roughly 40 months, 6.5 percent of those receiving semaglutide experienced a major cardiac event, compared with 8 percent in the placebo group. The margin was significant — but what surprised researchers most was that the benefit held even for participants who lost only modest weight. Semaglutide users lost an average of 10.2 percent of body weight, yet the cardiovascular protection appeared independent of how much weight was shed, pointing to mechanisms the drug triggers directly within the body's systems.
Professor John Deanfield, the study's lead author, called the findings transformative and argued the drug should be routinely prescribed for cardiovascular illness. The NHS began offering Wegovy for weight loss in 2023, but these results suggest a far wider clinical mandate may follow. Professor Jason Halford of the European Association for the Study of Obesity added that as costs fall, widespread NHS prescribing could generate substantial economic savings through a healthier, more productive workforce.
On the horizon, a newer compound called retatrutide — still in phase 2 trials — achieved 24 percent body weight loss over 48 weeks through a different mechanism, combining appetite suppression with enhanced fat burning. Researchers believe its effects may not yet have peaked. Together, these developments signal a field moving rapidly from weight management toward direct cardiovascular protection, and toward compounds of still-greater potency — leaving health systems to determine how quickly they can meet the scale of what science is now making possible.
A weight-loss injection used by millions could reshape how doctors treat heart disease. Researchers at University College London presented findings showing that semaglutide—the active ingredient in Wegovy and Ozempic—reduced the risk of heart attack, stroke, and cardiovascular death by 20 percent in a large international trial. The discovery, unveiled at the European Congress of Obesity in May 2024, has prompted leading cardiologists to compare the drug's potential impact to statins, the cholesterol-lowering medications that transformed heart disease prevention in the 1990s.
The study tracked 17,604 adults aged 45 and older across 41 countries. All participants had a body mass index above 27 and a history of cardiovascular events. Half received a weekly 2.5-milligram dose of semaglutide; the other half received a placebo. Over an average of 40 months, 569 people in the semaglutide group (6.5 percent) experienced a major cardiovascular event—heart attack, stroke, or cardiovascular death—compared with 701 in the placebo group (8 percent). The difference was stark enough to reshape the conversation around the drug's purpose and reach.
What surprised researchers most was that the cardiovascular benefit appeared independent of weight loss. Participants taking semaglutide lost an average of 10.2 percent of their body weight and 7.7 centimeters from their waist over four years, while the placebo group lost 1.5 percent and 1.3 centimeters respectively. Yet the heart protection held even for people who lost only modest amounts of weight, or who started with mild obesity. This suggests the drug works through mechanisms beyond simple weight reduction—that something in semaglutide itself shields the cardiovascular system in ways science is still mapping.
Professor John Deanfield, director of the National Institute for Cardiovascular Outcomes Research and lead author of the study, called the findings transformative. He noted that statins were once considered revolutionary for cardiology practice, and semaglutide could occupy similar ground. "This fantastic drug really is a gamechanger," Deanfield said, adding that the medication should be routinely prescribed for cardiovascular illness and that millions of people across the UK could be taking it within years. The NHS began prescribing Wegovy for weight loss in 2023, but these findings suggest a far broader clinical role.
The economic implications are substantial. Professor Jason Halford, president of the European Association for the Study of Obesity, predicted that as costs decline, the NHS could realize significant savings by prescribing the drug widely. Treasury officials are already considering the broader economic benefits—a healthier, more productive workforce means fewer sick days and greater economic output. With 7.6 million people in the UK living with heart or circulatory disease, according to the British Heart Foundation, the scale of potential impact is enormous.
Meanwhile, a newer competitor is emerging. Retatrutide, a weekly injection still in clinical trials, works through a different mechanism: it suppresses appetite while also helping the body burn more fat. In a 338-person phase 2 trial, participants lost 24 percent of their body weight over 48 weeks—substantially more than semaglutide or Ozempic achieve. Professor Naveed Sattar of the University of Glasgow, who has worked on weight-loss drug trials, suggested the drug may not have reached its plateau. "If we give this drug even longer, I think it could reach nearly 30 percent of someone's body weight," he said. Five or ten years ago, such results would have seemed impossible.
The convergence of these findings marks a turning point in how medicine approaches chronic disease. Semaglutide's cardiovascular protection, operating through pathways beyond weight loss, opens questions about how the drug might benefit other conditions of aging. The field is moving quickly—from weight loss as the primary goal to cardiovascular protection as a direct effect, and now toward even more potent compounds in development. What remains to be seen is how rapidly the NHS and other health systems can scale access, and whether the economic case for widespread prescription becomes as compelling as the clinical one.
Bemerkenswerte Zitate
This fantastic drug really is a gamechanger. Something else is going on that benefits the cardiovascular system beyond weight loss.— Professor John Deanfield, director of the National Institute for Cardiovascular Outcomes Research
In the next 10 years we'll see a radical change in the approach to healthcare. Once costs come down, the cost savings to the NHS will be significant.— Professor Jason Halford, president of the European Association for the Study of Obesity
Möchten Sie die ganze Geschichte?
Das Original lesen bei The Guardian ↗
Health & Medicine